Soleno Therapeutics Third Quarter 2025 Financial Results, Update on U.S. Launch of VYKAT(TM) XR

Soleno Therapeutics (NASDAQ: SLNO) reported third quarter 2025 results and a U.S. launch update for VYKAT XR on November 4, 2025. Key highlights: Q3 product revenue $66.0M, net income $26.0M for the quarter, and $556.1M in cash, cash equivalents and marketable securities as of September 30, 2025 (includes $230M gross proceeds raised in July). From FDA approval on March 26, 2025 through Sept 30, 2025: 1,043 patient start forms, 764 active patients, and 494 unique prescribers. Q3 product revenue rose >100% sequentially vs Q2. Company noted contingent consideration fair value of $19.5M tied to commercial milestones.

https://www.stocktitan.net/news/SLNO/soleno-therapeutics-reports-third-quarter-2025-financial-results-and-zirdksjin6na.html